Immuneering Corporation (IMRX) Key Metrics
IMRX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $232.3M
- Enterprise value
- $137.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 563.6
- Price / book
- 1.5 10-yr median 1.6
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.46
IMRX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIMRX valuation Price multiples at each fiscal year-end price.
IMRX returns How much profit the business earns on the capital it uses.
IMRX per-share figures Results divided by the shares outstanding at year-end.
IMRX financial health Debt, liquidity and how easily interest is covered.
IMRX efficiency & capital use Working capital cycle and where the cash goes.
IMRX valuation history
IMRX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IMRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IMRX price vs earnings per share
IMRX key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $289.6M | $66.0M | $208.9M | $128.0M | $425.6M | — | — |
| Enterprise value | $120.6M | $34.0M | $127.7M | $27.3M | $281.8M | — | — |
| Price / sales | — | — | — | 403.8 | 204.6 | — | — |
| Price / book | 1.3 | 1.6 | 2.3 | 1.2 | 2.7 | — | — |
| EV / sales | — | — | — | 86.1 | 135.5 | — | — |
| Earnings yield | −19.3% | −92.5% | −25.6% | −39.5% | −7.9% | — | — |
| Free cash flow yield | −15.7% | −83.5% | −23.6% | −35.0% | −7.3% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | 0.0% | — | — |
| Share price at fiscal year-end | $6.58 | $2.20 | $7.35 | $4.85 | $16.17 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.01 | $0.08 | $0.17 | $0.14 |
| Earnings per share | −$1.27 | −$2.04 | −$1.88 | −$1.91 | −$1.27 | −$1.26 | −$0.57 |
| Operating cash flow per share | −$1.03 | −$1.83 | −$1.72 | −$1.67 | −$1.17 | −$1.08 | −$0.33 |
| Free cash flow per share | −$1.03 | −$1.84 | −$1.74 | −$1.70 | −$1.17 | −$1.09 | −$0.33 |
| Cash per share | $3.93 | $1.21 | $3.01 | $4.00 | $5.67 | $2.75 | $1.02 |
| Book value per share | $4.96 | $1.38 | $3.19 | $4.16 | $5.93 | −$1.66 | −$0.48 |
| Tangible book value per share | $4.80 | $1.15 | $2.94 | $3.89 | $5.65 | −$1.66 | −$0.48 |
| Capex per share | $0.00 | $0.00 | $0.01 | $0.03 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.09 | $0.14 | $0.16 | $0.18 | $0.20 | $0.05 | $1.23 |
| Shares outstanding | 44.0M | 30.0M | 28.4M | 26.4M | 26.3M | 13.5M | 13.5M |
| Change in shares outstanding | +46.8% | +5.5% | +7.7% | +0.3% | +94.8% | 0.0% | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −43.1% | −92.5% | −53.4% | −38.0% | −50.2% | — | — |
| Return on invested capital (ROIC) | −159.3% | −539.1% | −497.8% | −383.6% | — | — | — |
| Return on assets (ROA) | −39.4% | −78.6% | −47.5% | −34.9% | −32.7% | −64.9% | −54.7% |
| Return on tangible assets | −24.9% | −133.6% | −56.0% | −43.8% | −21.0% | −44.3% | −54.7% |
| Free cash flow margin | — | — | — | — | — | −634.8% | −232.5% |
| Financial health | |||||||
| Total debt | $3.8M | $4.2M | $4.5M | $4.8M | $5.4M | $621,089 | $16.6M |
| Cash & short-term investments | $172.8M | $36.1M | $85.7M | $105.5M | $149.2M | $37.1M | $13.8M |
| Net debt | −$169.0M | −$32.0M | −$81.2M | −$100.7M | −$143.8M | −$36.5M | $2.8M |
| Debt / equity | 0.02 | 0.10 | 0.05 | 0.04 | 0.03 | — | — |
| Debt / assets | 0.02 | 0.08 | 0.04 | 0.04 | 0.03 | 0.02 | 1.18 |
| Current ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 | 27.83 |
| Quick ratio | 17.50 | 5.28 | 11.35 | 13.50 | 40.23 | 16.73 | 27.83 |
| Interest coverage | — | — | — | -51.0 | -167.8 | -400.5 | -17.9 |
| Working capital | $166.2M | $32.1M | $81.2M | $100.7M | $146.7M | $35.5M | $13.6M |
| Invested capital | $49.5M | $9.4M | $9.4M | $9.2M | $12.1M | −$59.0M | −$3.7M |
| Tangible asset value | $211.5M | $34.3M | $83.5M | $102.8M | $148.8M | −$22.5M | −$6.5M |
| Net current asset value | $162.7M | $28.3M | $77.1M | $96.2M | $141.6M | −$23.2M | −$6.6M |
| Graham net-net per share | $3.62 | $0.83 | $2.59 | $3.53 | $3.86 | −$1.73 | −$0.49 |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | — | $0 | $0 | — | — |
| Capex / revenue | — | — | 75,328.8% | 234.3% | 2.9% | 2.3% | 1.1% |
| Capex / depreciation | 0.40 | 0.22 | 0.97 | 2.68 | 0.38 | 0.67 | 1.14 |
| Stock-based compensation / revenue | — | — | 1,258,711.0% | 1,282.4% | 86.7% | 47.0% | 31.1% |
| R&D / revenue | — | — | 9,148,135.8% | 11,442.5% | 1,276.0% | 649.1% | 222.9% |
| SG&A / revenue | — | — | 3,796,015.6% | 4,924.1% | 397.7% | 134.5% | 141.1% |
| Efficiency | |||||||
| Days sales outstanding | — | — | 4,980.4 | 148.8 | 65.5 | 56.1 | 39.9 |
| Days of inventory on hand | — | — | — | -85,767.9 | -23,522.9 | — | — |
| Days payables outstanding | 914.3 | 1,041.2 | 1,257.7 | 5,250.2 | 455.0 | 253.1 | 88.0 |
| Cash conversion cycle (days) | — | — | 3,722.7 | -90,869.3 | -23,912.4 | -197.0 | -48.1 |
| Receivables turnover | — | — | 0.07 | 2.45 | 5.58 | 6.51 | 9.14 |
| Payables turnover | 0.40 | 0.35 | 0.29 | 0.07 | 0.80 | 1.44 | 4.15 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.14 |
| Average receivables | — | — | $6,208 | $129,228 | $373,075 | $355,025 | $209,940 |
| Average payables | $1.8M | $2.0M | $2.6M | $2.3M | $1.4M | $887,742 | $294,948 |
| Average inventory | — | — | — | −$37.2M | −$74.3M | — | — |
| Intangibles / total assets | 3.0% | 13.4% | 6.9% | 5.8% | 4.3% | 0.0% | 0.0% |
Computed from IMRX's annual financial statements (latest annual report filed March 6, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IMRX valuation and financial ratios
Immuneering earned a return on equity of −43.1% and a return on invested capital of −159.3% in fiscal 2025. It ended the year with $3.8 million of debt and $172.8 million in cash and short-term investments, a net cash position of $169.0 million. The share count rose 225.7% from 13.5M to 44.0M over 6 years.
See the IMRX income statement, the IMRX chart for price history, or the IMRX stock overview for the latest quote and news.
IMRX key metrics FAQ
What is Immuneering's return on equity?
Immuneering's return on equity (ROE) was −43.1% in fiscal 2025: net income of -$56.0 million on average shareholders' equity of $129.9 million.
What is Immuneering's ROIC?
Immuneering's return on invested capital was −159.3% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Immuneering have?
Immuneering had total debt of $3.8 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Immuneering's free cash flow yield?
Immuneering generated -$45.5 million of free cash flow in fiscal 2025, a free cash flow yield of −15.7% on its market value at year-end ($289.6 million).
What is Immuneering's current ratio?
Immuneering's current ratio was 17.50 at the end of fiscal 2025: current assets were 17.50 times current liabilities.